ArticleScience advances2025

Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models.

Tito Borner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.